Richard brings enterprise software and cloud experience from senior roles at Oracle and ADP, alongside venture capital operating experience as co-founder and chief executive of QantX.
Harry brings early-stage investment and deep science experience, holding a PhD in chemistry alongside roles at QantX and The Royal Society. He also has founding experience with Rude Fox Games.
The funding round was led by QantX Ventures and will support the development of a rapid prototyping tool for photonic chips.
"The LightCraft platform, in combination with the LightPort, gives businesses the tools to push the boundaries of what’s possible with integrated photonics. Customers can bring their ideas to life quickly and effectively, driven by the expertise of the Light Trace team. At Light Trace, we don’t just design—we build. This hands-on approach provides us with unique insights into the intricacies of photonic chip development, insights that we share with our customers to help fuel their success."
The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.
"We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions are diagnosed and treated."
The pre-seed round was led by Science Angel Syndicate and Fink Family Office to develop cold chain-free vaccine technology.
"Our goal are to make the transportation of vaccines and other life-saving biological materials more efficient and cost-effective while also reducing the carbon footprint of this critical supply chain. We are thrilled to have the support of our investors as we work towards this mission."
The seed round was backed by private investors establishing QantX Ventures to fund clinical development.
"We are excited to become part of the Neuronostics journey, they have pioneered innovative technology that will make a significant positive difference to the lives of many people around the world."
